[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538028":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":31,"locations":36,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"N-of-1 treatment with marketed drugs used on or off-label as per SOC.",[13],"Other: Patient-specific treatments",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","N-of-1 treatment with drugs accessed from SAP.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group 3","N-of-1 treatment with non-marketed investigational agents.",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Patient-specific treatments","Treatment will be decided specifically for the patient based on biomarker test results.",[9,15,19],[28],{"name":29,"affiliation":5,"role":30},"Amit Oza, Dr.","PRINCIPAL_INVESTIGATOR",[32],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","416 946 4450","amit.oza@uhn.ca",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University Health Network, Princess Margaret Cancer Centre","RECRUITING","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":46,"coordinates":47},"Point",[48,49],-79.39864,43.70643,{"lat":49,"lon":48},[52],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100538028","umbrella-study-for-single-patient-treatments-in-oncology-100538028",false,"NCT06285500","Umbrella Study for Single Patient Treatments in Oncology","UNIQUE: Umbrella N-of-1 Tumor Trials - Umbrella Protocol for Oncology Single Patient Protocols","UNIQUE","Inclusion Criteria \\& Exclusion Criteria:\n\nPatient's existing genomic information from tumor molecular profiling will be discussed in the hospital expert molecular tumor board rounds consisting of representatives from specialist genomic profiling and medical oncology departments to decide N of 1 treatment for the patient. The discussion will surround the best next therapeutic option in the patient's cancer subtype with or without clear standard of care guidelines. Therefore, specific eligibility criteria aside from individual patient's medical history is not applicable.","ALL","18 Years",{"count":66,"type":67},400,"ESTIMATED","2 Years","OBSERVATIONAL","The purpose of this study is to collect data for assessing the improvement of the overall response rate for the overall cohorts and the proportion of patients accessing precision targeted therapy.",[72,73],"Advanced Cancer","Rare Diseases",[75],"single patient protocols","2025-12-08",{"date":78,"type":79},"2025-12-16","ACTUAL",{"date":81,"type":79},"2024-02-01",{"date":83,"type":67},"2029-02-01",{"name":5,"class":6},1]